11th Jun 2018 11:31
LONDON (Alliance News) - Premaitha Health PLC said Monday it has signed an agreement with Canadian biotechnology engineering firm Coastal Genomics to develop advanced technologies for clinical DNA sequencing tests.
Premaitha Health said the technologies being developed will be "best in class" and will work across different applications.
The advanced technologies being developed will "enhance" aspects of Premaitha's in vitro diagnostic product portfolio.
Chief Executive Officer Stephen Little said: "In partnering with Coastal Genomics, we see a real opportunity to introduce improved processes which will optimise our existing workflow, reduce cost and improve overall efficiency of the screening process for our customers. Coastal Genomics have significant expertise in this field and we look forward to working together to develop this market leading technology."
Shares in Premaitha Health were up 3.0% Monday at 8.50 pence each.
Related Shares:
Premaitha Health